A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer’s disease, according to findings in the May issue of the Journal of Alzheimer’s Disease.
The molecule also reduced inflammation in the part of the brain responsible for learning and memory.
The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University, is the second mouse study that supports the potential therapeutic value of an antisense compound in treating Alzheimer’s disease in humans.
“It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer’s disease,” Farr said. “Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer’s disease.”
Farr cautioned that the experiment was conducted in a mouse model. Like any drug, before an antisense compound could be tested in human clinical trials, toxicity tests need to be completed.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Gamechanger: Blood test can predict if patients will develop Alzheimer's disease in the futureon December 1, 2020 at 9:14 pm
Scientists said Monday they had developed a way of predicting if patients will develop Alzheimer's disease by analysing their blood, in what experts hailed as a potential "gamechanger" in the fight ...
- New tests identify early changes in Alzheimer’s disease before symptoms appearon December 1, 2020 at 8:11 pm
Researchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop. The scientists developed new tools to detect ...
- First Alzheimer's blood test now on the market, without FDA approvalon December 1, 2020 at 1:00 pm
More than 5 million people in the United States and millions more around the world have Alzheimer's, the most common form of dementia.
- New blood test to help diagnose Alzheimer's comes with a caveaton December 1, 2020 at 10:27 am
The new test is not approved by the FDA and is not supported by the Alzheimer's Association. But advocates are encouraged by the research.
- First Alzheimer’s Blood Test Now On Sale Only With Doctor’s Orderon December 1, 2020 at 10:21 am
AP reports that the blood test has not been approved by the FDA and is not covered by insurance or Medicare. Its maker, C2N Diagnostics of St. Louis, charges $1,250 and offers discounts based on ...
- AI uses retinal scans to spot Alzheimer’son December 1, 2020 at 10:01 am
A new AI model that examines retina images for changes that point to Alzheimer's disease may one day help diagnose the disease.
- Could Dirty Air Help Speed Alzheimer's?on December 1, 2020 at 8:47 am
Older adults exposed to air pollution might have a heightened risk of abnormal "plaque" accumulation in the brain, a new study suggests. Plaques refer to clumps of protein called beta-amyloid that ...
- First blood test to help diagnose Alzheimer’s goes on saleon December 1, 2020 at 8:37 am
AP A company has started selling the first blood test to help diagnose Alzheimer’s disease, a leap for the field that could make it much easier for people to learn whether they have dementia. It also ...
- Blood test for Alzheimer's goes on sale without FDA approvalon December 1, 2020 at 7:44 am
St. Louis-based C2N Diagnostics has released a blood test that it says can detect Alzheimer's disease. The test is not yet FDA approved, and is not covered by insurance, costing up to $1,250.
- Cleveland-Area Resident Elected to Lead Alzheimer's Association Board of Directorson December 1, 2020 at 7:00 am
The Alzheimer's Association has elected Brian J. Richardson from Avon Lake, Ohio, as Chair of its Board of Directors. Richardson, who was first elected to the Association's Board of Directors in 2013, ...
via Bing News